Your Patients Need Cefepime — Here's How to Help Them Find It

When you prescribe Cefepime for a serious infection and your pharmacy tells you it's on backorder, the burden often shifts to you and your care team to find a solution. The ongoing Cefepime shortage means this scenario plays out daily in hospitals and outpatient settings across the country.

This guide provides practical, actionable steps you can take to help your patients access Cefepime — or find the best alternative when it's truly unavailable. For the broader shortage context, see our provider shortage briefing.

Current Availability: What You Need to Know

As of early 2026, Cefepime injection remains on the ASHP shortage list. Key points about the current supply:

• B. Braun: Manufacturing delays — no confirmed resupply timeline
• Apotex, Baxter, Hospira (Pfizer): Intermittent availability across different vial sizes and formulations
• Premixed frozen IV solutions: Supply has been inconsistent; some facilities report better availability of premixed bags than powder vials
• Regional variation: Availability varies significantly by distributor, GPO contract, and geographic region

The situation is fluid. What's unavailable today may be restocked tomorrow, and vice versa. Regular monitoring is essential.

Why Patients Can't Find Cefepime

Understanding the barriers your patients face helps you provide better guidance:

Hospital Formulary Restrictions

Many hospitals have placed Cefepime on restricted formulary during the shortage, limiting use to approved indications or requiring infectious disease consultation. Patients being discharged who need to continue IV antibiotics at home may find that their hospital's outpatient pharmacy or contracted home infusion company also has limited supply.

Limited Outpatient Options

Cefepime is an IV medication — patients can't fill it at a retail pharmacy. Their options are typically limited to hospital outpatient pharmacies and specialty home infusion pharmacies. If the home infusion company their insurance contracts with is out of stock, patients may feel they have no options.

Insurance and Access Barriers

Even when Cefepime is available at a specialty pharmacy, prior authorization requirements, insurance network restrictions, and cost-sharing can create additional barriers for patients transitioning to home infusion. Out-of-pocket costs for home infusion can be substantial — the retail price for Cefepime alone is approximately $363 for nine 2 g vials, plus infusion supplies and nursing visits.

What Providers Can Do: 5 Practical Steps

Step 1: Check Availability Using Medfinder

Use Medfinder for Providers to search for Cefepime availability across pharmacies and facilities. You can also direct patients and their caregivers to the tool so they can search independently. Medfinder provides real-time stock information that's more current than calling individual pharmacies.

Step 2: Contact Multiple Home Infusion Pharmacies

Don't rely on a single home infusion provider. Different companies source from different distributors, so one may have supply when another doesn't. Major national home infusion providers include:

• Option Care Health
• BioScrip (now part of Option Care)
• PharMerica
• Coram CVS/specialty infusion services
• Regional and independent specialty pharmacies

If the patient's insurance-preferred provider is out of stock, document the shortage situation — this can support a network exception or single-case agreement with the insurer.

Step 3: Be Flexible on Formulation

If one formulation of Cefepime is unavailable, another may be in stock:

• 2 g vials unavailable? Two 1 g vials can be used instead
• Powder vials unavailable? Check for premixed frozen IV bags (1 g/50 mL or 2 g/100 mL)
• Premixed unavailable? Powder vials with reconstitution instructions for the patient or home health nurse may be available

Adjust your prescription to match what's available, and communicate the change to the patient and their infusion team.

Step 4: Have Alternatives Ready

When Cefepime is completely unavailable, having a pre-considered alternative saves time and prevents treatment delays. Recommended alternatives by clinical scenario:

• Anti-Pseudomonal coverage needed: Ceftazidime 2 g IV q8h or Piperacillin-Tazobactam 4.5 g IV q6h
• Febrile neutropenia: Piperacillin-Tazobactam or Meropenem per IDSA guidelines
• Complicated UTI: Ceftazidime, or step-down to oral Levofloxacin if susceptibilities support it
• Intra-abdominal infections: Piperacillin-Tazobactam (often preferred due to anaerobic coverage)

For a comprehensive review of alternatives, see our alternatives to Cefepime guide. For drug interaction considerations when switching, see Cefepime drug interactions.

Step 5: Document and Communicate

Documentation of the shortage and your clinical decision-making is important for several reasons:

• Supports insurance appeals if the alternative is more expensive or requires prior authorization
• Creates a record for your antimicrobial stewardship program
• Helps the care team understand the rationale if questions arise
• May be needed if the patient transfers to another facility

Alternatives at a Glance

Here's a quick-reference comparison for the most common Cefepime alternatives:

• Ceftazidime (Fortaz): Third-gen cephalosporin, strong Pseudomonas activity, narrower Gram-positive coverage. 1-2 g IV q8h.
• Piperacillin-Tazobactam (Zosyn): Extended-spectrum penicillin/BLI, broadest anaerobic coverage, excellent for intra-abdominal infections. 3.375-4.5 g IV q6-8h.
• Meropenem (Merrem): Carbapenem, broadest spectrum, reserve for resistant infections or when other options fail. 1-2 g IV q8h.
• Ceftazidime-Avibactam (Avycaz): Cephalosporin/BLI combination, active against many resistant Gram-negatives. 2.5 g IV q8h. Significantly more expensive.

Workflow Tips for Shortage Management

• Build shortage protocols: Work with your antimicrobial stewardship team to develop standing protocols for Cefepime substitution. Pre-approved alternatives speed up care when shortages hit
• Monitor ASHP updates: Subscribe to ASHP shortage notifications for Cefepime to stay ahead of supply changes
• Communicate with discharge planning: Alert care coordinators and case managers about the shortage so they can start sourcing Cefepime (or alternatives) for home infusion before discharge day
• Educate patients proactively: When prescribing Cefepime, mention the shortage early and discuss backup plans. This reduces anxiety and delays if availability changes mid-treatment
• Use Medfinder: Bookmark Medfinder for Providers as a quick availability check during prescribing decisions

Final Thoughts

The Cefepime shortage demands proactive planning, flexibility, and good communication between prescribers, pharmacists, and patients. No single step will solve the problem, but the combination of real-time availability tools, formulation flexibility, pre-planned alternatives, and strong documentation can ensure your patients get effective treatment without dangerous delays.

Stay connected with your institution's antimicrobial stewardship team, keep the ASHP shortage page bookmarked, and use Medfinder for Providers to track availability in real time.

For related guidance, see our article on how to help patients save money on Cefepime.